- TM Capital served as exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in its sale to an investment vehicle sub-managed by Levine Leichtman Capital Partners
- UltiMed’s insulin pen needles, syringes and complementary products are critical offerings for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease
- UltiMed’s proprietary “dispense and dispose” solutions provide diabetes patients a safe and convenient way to store used sharps following injection
- LDI is a family office based in Indianapolis, IN, with more than a century of experience funding and operating high-potential, middle-market companies
- LLCP is an independent investment firm that has managed approximately $11 billion of institutional capital since inception
Client Testimonial
We selected the TM Capital team based on their prior experience with UltiMed and their expertise in transactions in the diabetes and animal health sectors. TM Capital did an outstanding job of presenting UltiMed’s many strengths and growth opportunities to the market, and their deep relationships with potential acquirers were key to our success. We particularly appreciate the senior team focus they brought to completing this transaction despite the emergence of the COVID pandemic in the midst of this assignment.”
- John Martin, VP of Corporate Development, LDI, Ltd.
